Fibroblasts as a practical alternative to mesenchymal stem cells.
Journal of translational medicine
confidence
Key findings
Review/concept paper discussing fibroblasts as a practical alternative to MSC in regenerative medicine; no clinical or biological endpoints reported.
View source on PubMed (PMID 30053821) ↗
- Sample size
- Not reported
- Population
- Not applicable (review/concept paper)
- Dosing
- Not reported
- Duration
- Not reported
- Route
- Not reported
- Blinding
- not_reported
- Controls
- not_reported
- Drug class
- regenerative therapy
Full abstract
Mesenchymal stem cell (MSC) therapy offers great potential for treatment of disease through the multifunctional and responsive ability of these cells. In numerous contexts, MSC have been shown to reduce inflammation, modulate immune responses, and provide trophic factor support for regeneration. While the most commonly used MSC source, the bone marrow provides relatively little starting material for cellular expansion, and requires invasive extraction means, fibroblasts are easily harvested in large numbers from various biological wastes. Additionally, in vitro expansion of fibroblasts is significantly easier given the robustness of these cells in tissue culture and shorter doubling time compared to typical MSC. In this paper we put forward the concept that in some cases, fibroblasts may be utilized as a more practical, and potentially more effective cell therapy than mesenchymal stem cells. Anti-inflammatory, immune modulatory, and regenerative properties of fibroblasts will be discussed in the context of regenerative medicine.